Glenmark’s Telma brand, containing Telmisartan, has been a leading name in the treatment of hypertension, heart failure, and prevention of heart attack and stroke for two decades. The brand’s strength can be attributed to its strong brand identity, which has helped Glenmark successfully launch multiple line extensions and brands with enhanced formulations. According to a report by Pharmarack, flagship brands like Telma have seen strong growth with a CAGR of over 10% in the last five years, with some doubling their sales.
A 2015 study by Harvard Business Publishing Education revealed that Telma was introduced by Glenmark in 2003, when Ramipril was the leading molecule for treating hypertension. Glenmark’s successful build-up of Telma to a Rs 1000 crore brand is believed to be a result of a well-executed plan, as reported in the Harvard Business Review in 2015.
The key factors that contributed to Telma’s success include Glenmark’s focus on a niche market, long-term vision, patient strategy, effective R&D and product development, strong distribution market, and low-key marketing. Additionally, the company’s data-driven approach and strategic partnerships also played a crucial role. With 16 brands under its umbrella, Telma Mother brand has a combined turnover of Rs 1036 crore. As a testament to its success, Telma remains the strongest brand under Glenmark’s umbrella, making it a household name in the Indian pharmaceutical industry.